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Migraine affects 23 .6 million people in the United States alone . Treatment
options can be sub-typed as abortive and preventative, as well as pharmacologic and non-
pharmacologic . Due to the debilitating nature of migraine, patients and physicians ofte n
rely heavily on abortive treatments . A review of the literature, along with a series o f
personal interviews suggests that preventative measures, used alone or with abortiv e
treatment, increase the patient's control over the migraines . Additionally, non-
pharmacologic interventions such as relaxation training, biofeedback, and dietar y
modification may offer migraine relief while improving the patient's quality of life . The
integration of several treatment avenues represents a growing change in western cultur e
toward prospective medicine, and will aid in maximizing treatment efficacy for migraine .
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Chapter 1: Introduction
Humans have suffered from migraine for at least two-thousand years, and i t
remains one of the most elusive conditions of our time (Sacks 1992). A debilitating
headache disorder, it is widely believed that migraine results from a combination o f
genetic and environmental factors, sometimes confounded by psychological conditions .
As a migraine sufferer for the past eleven years, I have tried various medications with
little to no alleviation . A few years ago I stumbled across diet modification as a
preventative tool for migraine and found that this approach offered more relief than I ha d
found with any medication . In this project I set out to determine whether all migraineur s
can benefit from a non-pharmacologic approach to migraine treatment and to examine th e
barriers that prevent migraineurs and physicians from utilizing a comprehensiv e
treatment plan .
Due to the incapacitating and overwhelming nature of migraine attacks, patient s
and physicians often seek abortive treatment for relief . However with migraine
pathophysiology yet to be fully understood, abortive treatment only affects the symptom s
of an unknown underlying mechanism . Alternatively, preventative medications can hel p
patients exert control over their migraines especially when comorbidities exist, but also
hold the potential for adverse side effects . Nonpharmacologic treatment lacks the level
of comparable research of pharmacologic options ; however, treatments such as
behavioral interventions may prevent migraines while also improving migraineurs '
overall quality of life . Given the limited efficacy of each treatment option and the wid e
range of factors contributing to migraine, migraineurs maximize control of their
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migraines by eliminating migraine triggers, aggressively utilizing non-pharmacologi c
therapy, and relying only minimally on abortive treatments .
In 1989, a group of researchers determined the prevalence, socioeconomic profile
and burden of migraine in the United States . They sent out a self-administered
questionnaire to 20,000 households in the United States, asking each individual over 12
years of age to respond to questions regarding symptoms, frequency, and severity of thei r
headaches and related disability . The results showed that approximately 18% of women
and 6% of men suffer from migraine, and that 23% of households contained at least on e
migraineur . These results were replicated by an identical study ten years later . In the
1999 study, it was found that an estimated 23 .6 million Americans suffer from migraine
(Lipton et al, 2001) . However Dr. David Mundall, a Eugene neurologist, suggests tha t
these numbers may underestimate the actual number of migraineurs in the United States ,
as many patients fail to report their symptoms (Dr . John Mundall, interview, 5 Apri l
2006) . Migraine is a difficult condition to diagnose and treat because 1) no diagnostic
test exists to define, ensure or differentiate idiopathic headache disorders 2) it is
considered a functional disease, in which the migraineur often continues work, play an d
social activities despite the reduction in overall quality of life and episodes of disabilit y
(May 2005) .
Migraine is more than a descriptive term for a bad headache (Dr . John Mundall ,
interview, 5 April 2006) . While permanent anatomical and psychological effects are no t
well understood, the disability associated with migraine results in a great burden for
patients, families and employers. It is estimated that 70% of migraineurs have impaire d
interpersonal relationships, and regular activities are limited during 78% of their attacks .
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Not only do migraine patients have to deal with the pain, but also the burden of los t
productivity, absence of control of the headache, and fear of the next attack (Solomon ,
1993) . In a personal interview, one migraineur explained, "My mom and I joke and cal l
it the `M' word, in fear if we talk or think about having one, we will actually trigger a
migraine" (Personal interviews, March/ April 2006). The quality of life of these patients
is impaired even between attacks . Migraine patients show more symptoms of emotional
distress, as well as disturbed contentment, vitality and sleep than those without an y
headache disorders (Dahlof and Dimenas, 1995) .
The economic burden of migraine is substantial, in both the amount of mone y
spent by patients and insurance companies for treatment, as well as the amount o f
corporate costs for absenteeism and ` presenteeism." Burton et al estimated the direct and
indirect corporate cost of migraine totaled between $21 .5 million and $24 .4 million,
suggesting the need for a corporate response to migraineur employees (Burton et al ,
2002) .
Families of migraineurs also bear a portion of the migraine burden . Smith's study
in 1998 examined the impact of migraine on the family, finding that 61% of migraineur s
reported their disorder had a significant effect on their families in terms of domestic an d
social activities, as well as interpersonal relationships . Twenty-five percent of the
migraine sufferers questioned reported that their headaches had a negative influence o n
their relationships with their spouse/partner (Smith, 1998) . In a collection of clinical
vignettes, Rueveni wrote that headache sufferers "frequently experience a sense of
isolation and guilt toward their spouses and children . . .family members can experience
confusion, anger and frustration in their attempts to help . . .(and) often wonder whether
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sufferers fake or exaggerate their headache pain or use the pain as a `tool' to contro l
others in the family" (Rueveni, 1992) . It becomes clear that migraine affects more than
just the 23 .6 million people that experience the actual pain .
Given the pain and resultant burden of migraine, why is it that over 60% o f
migraineurs in the U .S . have never sought, or have discontinued, medical care (Goadsb y
and Oleson, 1997)? In a 1992 survey, only 29% of men and 41% of women wit h
migraine reported ever receiving diagnosis for migraine (Lipton et al, 1992) . As a
functional condition, migraine sufferers may not feel the need to seek medical assistanc e
unless attack frequency and severity increase drastically . Patients list speed of onset ,
improved safety, affordable price, freedom from recurrence, consistent relief from ever y
headache as the most important factors in treatment (Goadsby and Oleson, 1997) .
Unfortunately, providing relief in all of these areas without completely understanding th e
physiology behind migraine proves to be a difficult task, leaving both patients an d
physicians frustrated and disillusioned. Treatment failure can occur for a number o f
reasons including patient noncompliance, inadequate medications or trial duration ,
medication overuse (causing rebound phenomenon) and incorrect original diagnosi s
(Loder and Biondi, 2005). As a result, some migraineurs simply accept their migraine s
as an integral part of their life . One 82-year-old migraineur elucidated, "If I don't have a
headache, something must be wrong," reflecting the sentiments of some migraineurs wit h
frequent headaches .
Migraine treatment can be partitioned into pharmacologic and non-pharmacologi c
groups . Within the pharmacologic group, physicians can prescribe abortive medication s
which are taken at the onset of an attack ; and/or preventative medications that are taken
5
every day. Non-pharmacologic treatment includes the elimination of potential triggers a s
well as behavioral interventions . Each treatment option can be employed alone, or i n
conjunction with one or more of the other options .
As the underlying mechanism and intersection of triggers that cause migraine
remain poorly understood, correct use of abortive medication allows the migraineur to
lead a functional life while suffering minimally from their migraines . Avoiding some of
the precipitating factors may not always be plausible, thus abortive medications provide a
legitimate option for many migraineurs . Unfortunately the vast majority of abortiv e
medications carry the potential for adverse side effects and overuse, the latter of whic h
can lead to rebound, or transformed migraine headache .
In addition to abortive drugs, physicians sometimes prescribe preventative, o r
prophylactic, drugs if a patient experiences a high frequency (more than once a week) o r
unusually severe migraine attacks . Researchers have found that the use of preventativ e
medicines as an adjuvant to abortive medicines often improves the patient's response t o
the abortive medicine (Ramadan et al, 1997) . These medications often help wit h
comorbidities such as depression, anxiety, and asthma . However like the abortive drugs ,
many prophylactics carry a significant potential for adverse side effects .
Another mode of treatment, not often suggested by physicians until migrain e
frequency and severity increases dramatically, is non-pharmacological treatment in th e
form of biofeedback therapy, cognitive behavioral therapy and strict avoidance o f
triggers . Since these treatments appear to be less effective than pharmacological
measures, physicians prescribe such treatment less often . Several precipitating factors o f
migraine have been identified through research, but more often through collective
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observations of patients' testimonies . These triggers include dietary factors such as
caffeine, monosodium glutamate (MSG) and cocoa ; environmental factors including
bright lights and changes in barometric pressure, as well as personal factors such as stres s
and/or stress letdown and physical exertion (Buchholz 2002) . Although only limited
research has provided insight into the role sleep and foods play in migraine pathogenesis ,
it has been suggested that sleep disturbance and food represent potentially modifiabl e
triggers of migraine (Millichap 2003, Kelman 2005) . Lifestyle modification generall y
presents a challenge that may seem to be a greater burden than the migraine itself . As
Wolff states, "one must appreciate that elimination of the headache may demand more i n
personal adjustment than the patient is willing to give . It is the role of the physician to
bring clearly into focus the cost to the patient of his manner of life . The subject mus t
then decide whether he prefers to keep his headache or attempt to get rid of it" (Wolf f
1963) . Personal adjustment, as Wolff uses it here, includes stress reduction, slee p
modification and other potentially avoidable triggers .
Regrettably, non-pharmacologic treatment appears underutilized in primary care .
In a 1999 review of clinical psychological interventions, McGrath states that the lo w
availability of psychological services on health care plans and lack of an "organize d
marketing arm" to inform physicians of the behavioral treatments prevents their us e
(McGrath 1999). Additionally patients may also be hesitant to utilize psychologica l
treatment, as not to inflate the stereotype of the mythical "migraine personality . "
Another barrier to non-pharmacological strategies results from the lack of research don e
with primary care patients . Most of the studies on non-pharmacological treatment s
involve patients in headache clinics, who have already surpassed the limits of primary
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care and experience refractory migraines. It is possible that non-pharmacological
treatment may provide more benefits if employed earlier in a patient's therapy regimen .
In order to understand the benefits and disadvantages of various lines of treatmen t
for migraine it is important to possess a basic understanding of the pathophysiology of




Even after 25 twenty-five years of well-aimed research, we still know relativel y
little about the pathophysiology of migraine . It is now widely accepted that migraine
falls within a continuum of headache disorders also containing chronic daily headach e
and cluster headache . In 1988 the International Headache Society published a guide t o
classification and diagnosis of headache disorders, cranial neuralgias and facial pain that
is used to distinguish between various headache disorders and administer the appropriat e
treatment (this classification system was updated in 2002, however the migraine criteri a
remained relatively unchanged) . As most headache patients suffer from multiple types o f
headaches, the I .H .S . states that it is ideal to classify the most important one or two type s
and direct a treatment plan based on that assessment . The I .H.S. describes migraine as an
"idiopathic, recurring headache disorder manifesting in attacks lasting 4-72 hours .
Typical characteristics of headache consist of one or more of the following : unilateral
location, pulsating quality, moderate or severe intensity, aggravation by routine physica l
activity, and association with nausea, photo- and phonophobia (Headache Classificatio n
Subcommittee of the I.H.S ., 2004) .
Migraine is typically diagnosed as "with aura" or "without aura ." The term
"aura" describes the neurological effects that some patients experience when cerebra l
blood flow decreases . The aura usually precedes the headache, but may occu r
simultaneously with the headache or after the headache begins . Some patients experience
aura without headache, nausea, photophobia or phonophobia (Headache Classificatio n
Subcomittee of the I .H.S ., 2004). Aura occurs in approximately 15% of the migraine
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population (Russell and Oleson, 1996), creating a different visual effect for each
migraineur as described in Box 1 .
Box L-Descriptions of aura'
	
g with migrain e
"It starts out with wavy lines and black spots that block out half ofthe words (whe n
reading) in one eye, then I usually lose my peripheral vision on either one or both
sides. This happens about 30 minutes before the pain starts
--Julie, 30-year-old female
"I begin to see bright spots and lose my vision . This is the major indicator that a
t migraine is coming and usually lasts for 30 minutes. I also get numbness to my
fingers and tongue .
-- Maria, 23-year-old female
Source: Personal interviews, MarchlApril 2006 (names have been changed to protect identitiy) .
Migraine stems from environmental and genetic factors . While the exact genetic s
of migraine are not fully understood, a pattern for maternal transmission has long bee n
recognized (Gardner 1999) . Currently researchers have made significant progress i n
determining the genetic basis for a rare form of migraine known as familial hemiplegic
migraine. These studies have laid the foundation for finding the genetic basis for other
types of headaches (Ferrari 2003) . However due to the difficulty in determining a
dominant or recessive pattern to inheritance, and other factors such as migraine on both
sides of the family and reliance on history for diagnosis, migraine is believed to be
genetically complex (Gardner 1999) .
According to Goadsby, migraine is in essence a disorder of sensory
dysmodulation, in which normal afferent activity is misperceived as being excessive du e
The aura would obscure my vision starting with the periphery and move towards the
center of my field of view. It lasted for a period of time ranging from 1-3 hours. but
al w ays stopped before vision was completely obscured. Migraine pain followed th e
resolution ofnormal vision by not more than a half hour.
-- Taylor, 21-year-old malec
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to dysfunction in brainstem regions that normally control and gate sensory neurona l
traffic. The result is excess throughput in the sensory thalamus that patients report a s
pain, and sensitivity to light (photophobia), sound (phonophobia), or head movement "
(Goadsby 2005) . This does not imply hyperexcitability of neurons, but actually that th e
migrainous brain does not habituate to stimuli in a normal way, leading to changes i n
cortical synchronization (Goadsby 2005) . Typically sensory neurons habituate, or in a
sense become accustomed to, sensory stimuli and decrease the frequency at which signal s
are sent to higher brain centers . With migraine the sensory neurons do not habituate ,
producing an effect similar to, but mechanistically different from hyperexcitation .
It is well understood that blood flow to the cranial and cerebral blood vessel s
increases during migraine, creating pain . Blood flow remains elevated in the brainste m
even after relief from the headache (Weiller et al 1995) . The development of 5-HT
receptor agonists (the triptans) has lent insight into the exact pathophysiology o f
migraine. While the exact cause remains unknown, we do know that for some reason th e
cranial blood vessels become dilated, potentially due to neurogenic inflammation, which
initiates a cascade of events in the brain (See Figure 1 on page 11) (Nozaki et al, 1992) .
The dilation activates afferent nerve fibers stemming from the trigeminal ganglion, whic h
sends the signal to the trigeminal nucleus caudalis in the brainstem. These nerve fibers
also release substance P, calcium gene-related peptide and neurokinin A (proteins tha t
cause vasodilation) upon stimulation, which perpetuates the vicious cycle of vasodilatio n
(Edvinsson et al, 1998) . Substance P causes weak vasodilation, but is not implicated i n
sensitizing nerve fibers in the trigeminovascular system . Instead substance P condition s
the nerve response to other inflammatory mediators as one of the first steps in migraine
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pathogenesis (Limroth et at, 1996) . Activation of neurokinin A receptors initiates the
release of nitric oxide, which is a powerful vasodilator implicated in the induction and
maintenance of migraine attacks (Jansen-Oleson et al, 2005) . CORP, another potent
vasodilator, is the most abundant peptide within the trigeminovascular system . In
addition to causing vasodilation CGRP may block substance P degradation, perpetuatin g
the first step in the migraine chain reaction (1.,imroth et al, 1996) . In the brainstem, as th e
pain is transmitted to higher brain centers, the release of more neuropeptides activate s
other ascending neural pathways, which may be the cause of symptoms related t o
migraine such as nausea and vomiting (Weiner et al 1995) .
t)csigncd and drawn by Tana Bryn
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Several possible candidate regions have been identified for migraine initiation ,
including the ventrolateral periaqueductal grey (PAG) and locus coeruleus (LC)
(Goadsby 2005) . The PAG is known to inhibit pain receptors in the trigeminovascular
system and it has also been suggested that activation of the PAG is associated with a n
animal becoming quiet and not engaging with its environment, similar to the behavio r
that many humans adopt when suffering from a migraine attack (Knight and Goadsby ,
2001, Knight et al, 2003, Bandler and Keay, 1996) . The LC also seems to be a plausible
nucleus because its widespread projections influence pain receptor and pan-sensory
processing (Goadsby and Duckworth, 1989 ; Goadsby et al, 1982) .
Numerous psychological, physical and environmental factors have been identifie d
as precipitating triggers to this mechanism; however the research to determine how the
wide range of precipitating factors initiates the cascade of events during a migrain e
remains to be seen .
Triggers
Two main factors exist in the occurrence of migraine: genetic predisposition an d
environmental factors, or triggers . Some triggers are difficult to control or avoid, such a s
weather/barometric changes, hormonal fluctuations, sensory stimuli (bright light ,
perfumes, etc .), physical exertion, irregular sleep and stress . According to Fragoso et al ,
both migraine and tension-type headache patients report prolonged anxiety and stressfu l
situations as the most important triggering factors, both of which almost always lead t o
an attack in migraineurs . Crying and menstrual cycles for women also rated high a s
triggers (Fragoso et al, 2003)
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Controllable triggers include dietary factors, caffeine intake and to a certain exten t
sleep and stress . While occasional intake of caffeine is not considered a trigger (caffeine
acts as a vasoconstrictor, thereby actually providing relief to some migraineurs) frequen t
intake can cause rebound headache similar to that caused by certain medications . Table 1
outlines some common dietary items believed to precipitate migraine, and the chemical
culprits involved .
Source : Millichap and Yee, 2005 .
Unfortunately, the broad range of triggers prevents researchers from finding a
common underlying factor in all precipitating factors . As such, in his book Heal Your
Headache, Dr. David Buchholz highlights the fact that avoiding all triggers can be
overwhelming for the patient (Buchholz 2002) . Each patient must find a balance betwee n
exposing themselves to certain triggers and controlling their headaches . The complexity
of precipitating factors can be perplexing to patients presented with a generalized plan o f





Hot dogs, ham, cured meats
Dairy products, yogurt
Fatty and fried food s










Nitrites, nitric oxid e
Allergenic proteins (casein, etc . )
Linoleic and oleic fatty acids
Monosodium glutamate




Stress hormone release, hypoglycemia
*ice cream headache is probably a cold-induced vasoconstrictor reflex
response .
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trigger avoidance. Box 2 illustrates the different triggers for several migraineurs
elucidated from personal interviews (Mi€raineur interviews, 2006) .
Source : Personal interviews, March'April 2006 (names have been changed to protec t
identitiy) .
Although some triggers such as hormones and diet appear common, it is th e
combination of various triggers along with varying levels of predisposition tha t
necessitate individualized treatment plans for migraineurs . In addition, some trigger s
may affect a greater response in certain patients while only minimally affecting others .
ox 2.-Examples of migraine ggers in a small sample of women
beth, 22 : oversleeping, diet (bologna, sauces, chocolate, cheese and
caffeine)--although moderation of these items does not present a problem,
stress letdown
aria, 23: stress, hormones, diet (too much dairy or caffeine), dehydration, bright
light
oanne, 49: staying up late and getting up early, stress, hormones, being in a ho t
stuffy room
Alecia, 53 : hormones, diet (MSG, artificial sweeteners, chocolate), bright light fo r
a prolonged period of time, excessive physical exertion, crying, sleeping
with face partially under the covers (reduced oxygen intake) .
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Chapter 3: Types of Treatment
Pharmacologic Acute Treatment
The evolution of migraine treatment has progressed significantly in the pas t
twenty years . Some physicians still use conventional step care methods in which simpl e
analgesics are prescribed after the initial migraine diagnosis, and the level and type o f
medication is adjusted based on the patient's success with the analgesic . The treatment
becomes more specific as the previous line of treatment fails to help . This can be
implemented within the duration of a single headache, or over the course of severa l
attacks (Figure la and lb) . In 2001 Lipton and Silberstein proposed a more effectiv e
system of stratified care, in which treatment is individualized to each patient based o n
their presenting level of headache . Stratified care involves a more thorough assessmen t
of treatment needs and the physician and patient work together to create an individualize d
treatment plan (Figure lc) . Lipton and Silberstein reported that stratified care ultimatel y
resulted in a greater headache response rate when compared with the step-care metho d
(Lipton and Silberstein, 2001) .
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Figure 2 .--Step care vs . Stratified Care for the Choice of Acut e
Migraine Treatments
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Source: Lipton and Silberstein, 200 1
In stratified care, physicians recognize that patients presenting with migraine a t
different stages of progression may require different medications . Recent research has
increased the options for acute migraine treatment . Table 2 (pg . 17) outlines the mos t
common abortive medications used in the United States, compiled from U .S . Headache
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Consortium guidelines (described below) as well as specific studies directly related to
each treatment option .
In 1998, a multi-disciplinary panel of representatives from several medica l
professional organizations convened to create a set of clinical practice guidelines for
headache, including the efficacy and evidence ratings of medications listed in Table 2 .
They accomplished this by analyzing all relevant controlled trials for headache treatmen t
between 1966 and 1996. They generated four separate sets of guidelines, each dedicate d
to a separate type of management decisions . The four groups consisted of diagnosti c
testing, pharmacological management of acute attacks, migraine-preventative drugs an d
behavioral and physical treatments for migraine . After evaluating the pertinent studies
the panel assigned each type of treatment within the four groups a letter grade of A, B o r
C based on the strength of evidence supporting the study . They also analyzed the clinica l
efficacy of each drug (Box 3) (McCrory et al 1998) .
lg ox 3.-U.S. Headache Consortium Scales .for Strength of
	
ge and
for Acute Migraine Treatment s
Strength of Evidenc e
A. Multiple well-designed randomized clinical trials, directly relevant to th e
recommendation, yielded a consistent pattern of findings .
B. Some evidence from randomized clinical trials supported the recommendation, but th e
scientific support was not optimal . For instance, few randomized trials existed, th e
trials that did exist were somewhat inconsistent, or the trials were not directly relevan t
to the recommendation . An example of the last point would be the case where trial s
were conducted using a study group that differed from the target group for the
recommendation .
C. The U .S. Headache Consortium achieved consensus on the recommendation in th e
absence of relevant randomized trial s
Clinical Effect
0 Ineffective: most people get no improvemen t
+ Somewhat effective: few people get clinically significant improvemen t
-H- Effective: some people get clinically significant improvement
+++ Very effective : most people get clinically significant improvement
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This information, along with details concerning side effects and contraindication s
are included in Table 2 in order to effectively compare various abortive migrain e
treatment strategies . Acute medications allow for fine tuning in individualized treatmen t
plans, increasing options for patients with certain comorbidities and preference s
(Ashkenzi and Silberstein, 2003). While several abortive medications are readil y
available, the triptans remain the only migraine-specific medication available today .
According to Goadsby, serotonin receptor agonists developed in the early 1990s ,
also known as triptans, represent "the most important advance in migraine therapeutics i n
the four millennia that the condition has been recognized" (Goadsby 2005) . The triptans
work as 5-HTlbnd receptor agonists, mimicking the effects of serotonin on 5-HT1bn d
receptors (Goadsby 1997) . Triptan molecules bind to these receptors on the crania l
vessels, inhibiting the release of the vasoactive peptides, allowing the vessels to constric t
to normal diameter (Longmore et al, 1997) . The 5-HT Id receptors are also locate d
throughout the trigeminal nerve fibers, more specifically on the trigeminal ganglion an d
trigeminal nucleus caudalis . When bound by triptan molecules, these receptors preven t
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All triptans work by the same basic mechanism of binding to serotonin receptor s
within the brain and periphery . Differences between the triptans include time of onset ,
bioavailability, selectivity, and interactions with other drugs (Ferrari 1997 ; Goadsby and
Hargreaves, 2000) . The presence of identical serotonin receptors in the coronary arteries
presents a potential setback for the triptans, as binding to the coronary receptors can lea d
to adverse coronary events. The Imitrex (sumatriptan) drug information pamphlet lists
coronary artery vasospasm, transient ischemia, myocardial infarction, ventricula r
tachycardia and ventricular fibrillation, cardiac arrest, various cerebrovascular events an d
death as possible side effects to the drug (Imitrex package insert) . However since the
concentration of 5-HTlbna receptors is much higher in the cranial vessels, and the primary
receptor for coronary constriction is of a different 5-HT class, the triptans are considere d
safe for migraine treatment (Longmore et al, 1997) .
All abortive medications have the potential to cause rebound, or transforme d
migraine headache, if overused . Classic rebound headache is classified by the I .H.S . as
headache induced by or due to substance withdrawal ((Headache Classificatio n
Subcomittee of the I .H.S ., 2004) . This can quickly worsen to chronic daily headach e
(CDH), often recognized as the presence of headaches for more than 15 days per month ,
lasting longer than 4 hours and presence for at least one year (Konno et al 1999) .
Patients with CDH may be the most difficult headache patients to treat, as they ofte n
develop physical, emotional and drug dependencies and reduced coping skills . Drug-
induced rebound headache is the most common cause of CDH in patients attendin g
specialty clinics in the United States (Silberstein and Lipton, 1997 ; Siniatchkin et a l
1999) .
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None of the abortive medicines specifically target early processes in the migrain e
mechanism, with the exception of the triptans and caffeine containing analgesics . Instead
they work as general pain-killers (e .g. analgesics) or vasoconstrictors (e.g. ergotamine )
and may or may not directly affect the migraine mechanism . Even the mode in which
triptans inhibit migraines remains limited, as increasing evidence has suggested t o
leading neurologists that migraine is primarily a neurological problem (Goadsby et a l
2002) . As listed in Table 2, triptans have the potential to induce serious adverse effects .
Simple analgesics and NSA1Ds can cause gastrointestinal disturbances if taken to o
frequently and also are a major culprit in rebound headache (Rapoport et al 1996) .
Barbituate hypnotics, although effective, contain butalbital-a chemical implicated i n
poor migraine control, disability, drug induced headaches and withdrawal symptoms
(Wenzel and Sarvis, 2002) . Ergot alkaloids can complicate several comorbidities i n
migraineurs, and like opiate analgesics and corticosteroids can cause serious side effect s
as well as early dependence .
With advances in migraine research, physicians may soon be able to phase out
prescriptions of harsh, non-specific migraine medications . In 2005 Goadsby compiled a
list of potential neuro-active drugs and potential targets for both preventative and acut e
migraine treatment. For migraine prevention, inhibition of cortical spreading depression
and voltage-gated calcium channels appear to hold major promise . Many more targets
exist for acute treatment, including serotonin receptors (different that the receptors tha t
triptans target), glutamate receptors, nociceptin opiod receptor-like 1 (ORL) receptors ,
vanilloid receptors, cannabinoid receptors and orexin receptor modulators (Goadsby
2005) .
22
vanilloid receptors, cannabinoid receptors and orexin receptor modulators (Goadsb y
2005) .
The development of neurally acting drugs could increase treatment efficacy an d
reduce side effects for migraineurs choosing abortive medication, as the new medication s
would ideally inhibit the migraine earlier in the causative process .
Pharmacologic Preventative Treatmen t
Several reasons exist for early implementation of preventative therapy in th e
treatment of migraine. It has been long recognized that episodic migraine can evolve i n
to a chronic headache disorder that is more difficult to treat . The progression of this type
of disorder may be redirected with early implementation of preventative therapy (Lode r
and Biondi, 2005). Several studies have shown that migraine patients tend to suffe r
lower quality of life during, and also between, migraine attacks . Part of the explanatio n
for this effect is that patients are often forced to rely on unsatisfactory acute treatment s
for attacks of varying severity and unpredictable onset (Dahlof and Dimcnas, 1995) . For
these patients, preventative therapy offers a better chance at predicting the onset of a n
attack because patients retain better control of their migraines . Box 4 summarize s
indications for migraine prevention .
Source : Loder, 2005 .
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Preventative treatment does more than protect migraineurs from episodic pain .
Recent research suggests that migraines may have permanent anatomical effects on
certain regions of the brain. More specifically, Welch et al found that migraineurs wer e
more likely to have non-heme iron deposits in areas of the brainstem corresponding to th e
periaqueductal gray matter in the brain, an area important in the regulation of ascendin g
pain signals (also a potential control center for migraine) . It is possible that chroni c
activation of these structures, along with the resultant hyperemia, may lead to free radical
formation, neuronal injury, and the observed iron deposition (Welch et al, 2001) . The use
of preventative medication can help to avert these unwanted anatomical changes .
Unfortunately, similar to the abortive medicines, no preventative medicine exist s
solely for migraine prevention . However several medications, including topiramate ,
divalproex sodium, propanolol and timolol have garnered FDA approval for migraine
prophylaxis . A summary of prophylactic medications prescribed in the United States i s
summarized in Table 3 on page 25 . The evidence for topiramate and botulinum toxi n
became available after the U .S. Headache Consortium convened, thus efficacy and
evidence ratings were not available for analysis . The U.S . Headache Consortium use d
the same criteria for efficacy and evidence ratings with abortive and preventative
medications . Preventative drugs are not prescribed in a specific line of treatment like th e
abortive medications. Instead, physicians examine any existing comorbidities and pick a
medication that will treat both conditions with minimal side effects . For example, a
patient presenting with both migraine and depression could potentially benefit from a n
anti-depressant medication . The medication treats both conditions by separate
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mechanisms (John Mundall, interview, 5 April 2006) . If no comorbidities exist, the
patient and physician work to find a medication that produces the fewest side effects .
To date, topiramate has been the most studied drug for migraine prophylaxi s
(Brandes and Lewis, 2005) . It seems likely that anti-epileptic drugs, also calle d
neuromodulators for their modulatory effect on neural and cortical hyperexcitability, ar e
more effective in preventing not only the underlying mechanism of migraine but also th e
neuralplasticity and progressive CNS injury mentioned above (Loder and Biondi, 2005) .
Nevertheless, the efficacy of all migraine prophylactic drugs remains limited until mor e
is understood regarding the pathophysiology of migraine .
The use of botulinum toxin type A (BOTOX) has recently been indicated as a
potential prophylactic treatment for patients with refractory migraine . This was
discovered anecdotally by patients receiving BOTOX injections for facial wrinkle -
reduction, who then realized that the injections appeared to decrease their headach e
frequency. The treatment involves injection of BOTOX every 3-6 months into a fixe d
fronto-temporal site . Although a few double-blind, placebo-controlled studies have bee n
performed on highly selected groups of patients suffering from chronic refractory
headaches, more studies in the future with primary care migraineurs will indicate whethe r
BOTOX demonstrates effective migraine prevention (Dodick et al, 2005) .
The use of medications with vascular effects, such as beta-blockers and calciu m
channel-blockers, is limited by several contraindications and adverse side effects .
Additionally, the emerging understanding of migraine as a neurological disease, a s
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Non-pharmacologic Preventative Therap y
All migraineurs, regardless of contraindications or severity of migraine, retain th e
ability to make lifestyle changes to prevent the frequency and severity of attacks . Non-
pharmacological options also include behavioral interventions such as biofeedback an d
relaxation training . Several barriers exist to the use of preventative therapy, bot h
pharmacological and non-pharmacological, in migraine treatment . First, many patients
do not receive the correct diagnosis of migraine . Second, physicians may not be familiar
with effective preventative agents andlor simply do not view migraine as a chroni c
serious illness that causes disability in otherwise healthy patients . Lastly, poor patient
compliance often complicates effective treatment, as sometimes patients do no t
understand why they have to take a medication or practice daily lifestyle changes for a
problem that occurs sporadically (Loder and Biondi, 2005) .
Though not widely studied, the use of non-pharmacologic preventative therapy a s
an adjuvant to abortive therapy may provide significant relief from migraine attacks ,
while also giving the migraineur significant control over their condition . McGrath states ,
"The use of psychological interventions to enhance compliance to treatment or treatment
effects is an underutilized resource. Psychological measurement is also critical i n
development and understanding of quality of life scales and the examination of decision-
making by patients in taking medication" (McGrath 1999) . According to the U .S .
Headache Consortium, the indications for behavioral and physical treatments are as
follows (Campbell et al, available at http :l/www.aan .com, accessed 4 April 2006) :
a) patient preference for nonpharmacological interventions ;
b) poor tolerance for specific pharmacological treatments ;
c) medical contraindications for specific pharmacological treatments ;
d) insufficient or no response to pharmacological treatment ;
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e) pregnancy, planned pregnancy, or nursing ;
f) history of long-term, frequent, or excessive use of analgesic or acute
medications that can aggravate headache problems (or lead to decreased
responsiveness to other pharmacotherapies); and
g) significant stress or deficient stress-coping skill s
While all the indications listed represent excellent reasons to initiate preventativ e
therapy, an analysis of studies indicating that migraineurs experience psychologica l
abnormalities during the headache phase suggests that behavioral interventions ma y
provide a greater benefit to the patient than treatment purely medicinal treatment (Brand t
et al 1990; McGrath 1999) . As Sacks pointed out, "It would be cruel and pointless to
deny any medication to an acutely suffering patient, but it is another matter altogether t o
tout any form of drug therapy as the sole treatment of severe, frequently-recurrin g
migraines" (Sacks 1992) . Physicians and patients must find a balance between acutel y
treating migraine attacks while aggressively working to prevent their occurrence .
The most commonly used behavioral interventions are biofeedback, relaxation
therapy and cognitive therapy . These therapies not only work to reduce migrain e
symptoms but also improve patients' quality of life . In a study of migraine patients at th e
Gothenburg Headache Clinic in Sweden, Dahlof and Dimenas found that migraineurs
perceived greater emotional distress, a lesser sense of well-being, as well as disturbe d
contentment, vitality and sleep even between migraine attacks (Dahlof and Dimenas ,
1995) . As behavioral interventions emphasize the learning of self-control and self-
maintenance strategies to be used outside of treatment, the implementation of thes e
strategies may maximize patients' control of their migraine and also improve their qualit y
of life (McGrath 1999) . A summary of behavioral interventions is provided in Table 4
below .
2 8
Source : Mcgrath, 1999
In addition to behavioral interventions, many patients eliminate potential trigger s
in an effort to prevent migraine attacks . The most common elimination occurs with
dietary triggers . The eradication of dietary triggers can be delicate though, as physician s
must ensure that patients avoid diets resulting in B 12 or other vitamin deficiencie s
(Holroyd and Mauskop, 2003) . Patients eliminate all potential dietary triggers and the n
reintroduce the products one by one in order to identify potential triggers . Bic et a l
concluded that a low-fat diet may decrease the frequency, duration and severity o f
migraine headaches (Bic et al, 1999) . This conclusion was reached based on reviewin g
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literature suggesting that a) overall levels of free fatty acids rose by more than 10 %
during a migraine attack, b)fatty foods are also often high in linoleic acid, which is a
prostaglandin (a vasodilator) precursor and c) high dietary fat intake increases bloo d
platelet aggregation, which in turn releases serotonin, reducing the amount available fo r
normal brain function (Anthony 1978 ; Horrobin 1977, Bic et al 1999) .
In addition to diet, it may be beneficial to examine a migraineurs sleep patter n
when assessing treatment modalities . Paiva et al found that 55% of patients awakening
with headache reflected a sleep disturbance . Each patient was treated for the sleep
disorder, and 100% reported improvement of headache symptoms while 65% reporte d
complete resolution (Paiva et al 1997) .
Non-pharmacological treatment proves to be beneficial by allowing the patient
more control over their migraines . Rebound headache has proven to be one of the bigges t
problems with abortive medications. Patients experiencing frequent migraines requirin g
abortive medication more than twice a week often take abortive medication more
frequently than the recommended allowance, finding that they need to take a greate r
amount each time the headache comes back . In essence as the medication wears off, th e
migraine returns stronger than before . Thus the patient takes more medicine, and
becomes dependent on the drug . The only way to cure rebound headache is by quitting
the medication "cold turkey" style and suffer from debilitating headache(s) until th e
rebound phenomenon wears off (Dr. John Mundall, interview, 5 April 2006) . This
problem can be at least ameliorated, if not completely avoided, by non-pharmacological
treatment plans .
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Chapter 4 : Conclusion
Epidemiological studies within the last twenty years suggest that migrain e
represents a remarkably common cause of disability in patients of all ages, races, gender s
and personalities (Lipton et al 2001 ; Lipton and Bigal, 2005 ; Lipton and Bigal, 2005) .
Research in both acute and preventative migraine therapies ideally will provid e
migraineurs with even more options for treatment, promote the use of individualize d
treatment plans, and lend greater insight to the pathophysiology of migraine . In addition ,
organizations like the World Headache Alliance and Lifting the Burden work to "increas e
awareness and understanding of headache as a public health concern with profound socia l
and economic impact," offering emotional and psychological support to migraineur s
worldwide (World Headache Alliance, available at http://www.i-h-s .org, accessed 2
February 2006) .
The use of preventative measures for migraine treatment represents a growin g
trend toward prospective care in all fields of medicine . Snyderman and Yoediono asser t
that "current approaches to health care are largely reductionist, based on the concept tha t
a disease is due to a pathologic event initiated by a specific initiating factor and that if th e
defect is found, it can be reversed and fixed" (Snyderman and Yoediano, 2006) . While
this approach works with some diseases, the evolution of almost all diseases, includin g
migraine, is comprised of more variables than the `find it and fix it' concept implie s
(Snyderman and Yoediano, 2006) (Figure 2) .
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With increasing research regarding migraine genomics, the model of diseas e
emergence can be readily applied to migraine therapy in the form of personalized
treatment plans . Loder and Biondi emphasizes this theory, concluding that "the future o f
migraine prevention will involve the development of evidence-based diseas e
management approaches to prevent the evolution of disability, medication overuse, an d
psychosocial morbidity that now characterize a subset of migraine patients" (Loder an d
Biondi, 2005) . It has been increasingly important to consider migraine as a process ,
reaction and experience simultaneously (Sacks 1992). In addition, it is imperative to
avoid the false systems partitioning that suggests migraine results strictly from
neurological or vascular origin . If migraine affects neural, vascular and psychologica l
processes, why not create a treatment plan that addresses each affected area of the brain ?
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As the nervous and vascular systems are complexly intertwined, it may b e
counterproductive to look for a migraine origin in just one system-perhaps migrain e
originates from a synergic combination of several existing factors that alone would no t
induce an attack.
Not only is it essential to examine various physiological systems in treating
migraine, but to also analyze the various physiological and psychological symptoms tha t
each patient presents with to create a complete, individualized treatment plan . No two
migraine patients are alike, and must be treated accordingly . This individualized ,
integrative treatment can be achieved by including behavioral interventions fo r
prevention and consequent psychological effects, preventative medication as needed, an d
minimal use of abortive medication for breakthrough attacks . Ideally this comprehensive
approach, incorporating pharmacologic and non-pharmacologic, acute and preventative
treatments, will increase treatment efficacy and allow migraineurs to maximize contro l
over their headaches .
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Appendix A.-Glossary of Terms
5-HT receptors-serotonin receptors, 5-HT Ib and 5-HTId represent different subtype s
abortive- providing or concerned with short-term medical care
acute-see acute
afferent-conveying impulses toward the central nervous syste m
analgesic-an agent that alleviates pai n
anti-cholinergic-inhibits acetylcholine receptor s
anti-emetic-used or tending to prevent or check vomitin g
aura-a subjective sensation (as of voices or colored lights or crawling and numbness )
experienced before an attack of some nervous disorders (as epilepsy or migrain e
bioavailability-the degree and rate at which a substance (as a drug) is absorbed into a
living system or is made available at the site of physiological activity
blepharoptosis-drooping or abnormal relaxation of the upper eyeli d
comorbidity-a condition existing simultaneously with and usually independently o f
another medical conditio n
contraindication-something (as a symptom or condition) that makes a particular
treatment or procedure inadvisabl e
coronary-of, relating to, affecting, or being the coronary arteries or veins of the hear t
diplopia-a disorder of vision in which two images of a single object are seen (as from
unequal action of the eye muscles)-double visio n
dysrhythmia-an abnormal rhythm ; especially : a disordered rhythm exhibited in a
record of electrical activity of the brain or hear t
glutamate-excitatory neurotransmitter s
habituation- a : tolerance to the effects of a drug acquired through continued us e
b: psychological dependence on a drug after a period of use
hepatic-of, relating to, affecting, or associated with the liver
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hyperemia-excess of blood in a body part (as from an increased flow of blood due to
vasodilation)
hyperthermia-exceptionally high fever especially when induced artificially for
therapeutic purposes
ischemic-deficient supply of blood to a body part (as the heart or brain) that is due t o
obstruction of the inflow of arterial blood (as by narrowing of the arteries )
migraineur-an individual who experiences migraines
neurogenic inflammation-swelling of tissue induced, controlled, or modified by nervous
factors
oligohidrosis-deficiency in perspiration
presenteeism-reduced work efficiency while still remaining at the work site
pan-sensory--involving a wide range of sensory nerve s
paresthesia a sensation of prickling, tingling or creeping on the skin having no objectiv e
cause and usually associated with injury or irritation of a sensory nerve or roo t
pharmacologic-a drug-based medical treatment
prophylactic-guarding from or preventing the spread or occurrence of disease or
infection
refractory-resistant to treatment or cure
selectivity-the quality, state, or degree of being selectiv e
sick sinus syndrome-a cardiac disorder typically characterized by alternatin g
tachycardia and bradycardia
subcutaneous-under the skin
substance P-neuropeptide widely distributed in the brain, spinal cord and periphera l
nervous system, and that acts across nerve synapses to produce prolonge d
synaptic transmissio n
thalamus-the largest subdivision of the diencephalon that mainly consists of a mass o f
nuclei that serve to relay impulses and especially sensory impulses to and from the
cerebral cortex
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trigeminovascular system-refers to the complex of the trigeminal nerves and offshoot s
with the vascular system of the brain
vasoactive-affecting the blood vessels especially in respect to the degree of thei r
relaxation or contraction
vasoconstrictor-an agent (as a sympathetic nerve fiber or a drug) that induces or
initiates vasoconstriction
vasodilation-widening of the lumen of blood vessels
Note : Information adapted from the National Library of Medicine and National Institute s
of Health, available at http :// www.nim.nih.gov/medlinepluslmplusdictionary.html ; and
Merriam-Webster Dictionary, available at http :l/www.m-w.com.
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